Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Pharmaceutics|September 27, 2025
Optimizing Dose Conversion from IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling StudyZeyar Mohammed Ali, Beatriz Fernández-Alarcón, Pere Fontova, et al.
Journal of Clinical Medicine|June 18, 2020
Long-Term Effects in Bone Mineral Density after Different Bariatric Procedures in Patients with Type 2 Diabetes: Outcomes of a Randomized Clinical TrialFernando Guerrero-Pérez, Anna Casajoana, Carmen Gómez-Vaquero, et al.
Obesity Surgery|August 18, 2019
Changes in Bone Mineral Density in Patients with Type 2 Diabetes After Different Bariatric Surgery Procedures and the Role of Gastrointestinal HormonesFernando Guerrero-Pérez, Anna Casajoana, Carmen Gómez-Vaquero, et al.
Molecular Cancer|May 29, 2024
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progressionTorben Redmer, Martin Raigel, Christina Sternberg, et al.
Pharmaceutics|May 27, 2023
The Effect of Intracellular Tacrolimus Exposure on Calcineurin Inhibition in Immediate- and Extended-Release Tacrolimus FormulationsPere Fontova, Lisanne N van Merendonk, Anna Vidal-Alabró, et al.
Clinical Pharmacology and Therapeutics|February 24, 2021
Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant RecipientsPere Fontova, Helena Colom, Raül Rigo-Bonnin, et al.
Therapeutic Drug Monitoring|December 8, 2025
Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP FormulationAnna Vidal-Alabró, Pere Fontova, Zeyar Mohammed Ali, et al.
International Journal of Cancer|November 24, 2018
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemiaEriong Lee-Vergés, Bola S Hanna, Haniyeh Yazdanparast, et al.
Pageof 9